Back
OPPT
Magellan Global Opportunities Fund - Active ETF
🇦🇺 ASX
👑 Overview
📈 Performance
💰 Distributions
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
-0.67%
Annual Growth
4 years average annual capital growth
💰
17.99%
Annual distribution yield
Based on the most recent distribution
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
6
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Magellan Global Opportunities Fund - Active ETF
📈 Performance
Price History
-2.75%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →📙 Top Holdings
Show moreTop holdings information is not yet available for this fund. For more information please visit the fund manager's website.
💰 Distributions
Payouts
💰 Annual Distribution Yield*
17.99%
💰 Annual Distribution Earnings Per $1,000 invested**
$179.89
💰 Most Recent Distribution Franked Percentage Estimate
0.00%
💰 Average Distribution Franked Percentage Estimate
0.00 %
💰 Distribution reinvestment
* Based on the most recent distribution
** Calculated by multiplying the most recent distribution yield by $1,000
Estimate your distribution
If you held
$
of OPPT, your last distribution payment(s) would have been:
$ 589.81
on Tue Sep 30 2025
$ 600.49
on Mon Jul 21 2025
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Distribution History
1Y
5Y
10Y
Graph
Table
Year
Yearly Distribution Earnings Per Share
Franking Estimate
2025
$0.32
0.00%
2024
$0.05
0.00%
2023
$0.05
0.00%
2022
$0.05
0.00%
2021
$0.00
0.00%
2020
$0.00
0.00%
2019
$0.00
0.00%
2018
$0.00
0.00%
2017
$0.00
0.00%
2016
$0.00
0.00%
💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$1.77
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in OPPT
6
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in OPPT
N/A
OPPT investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
17%
50k - 100k
83%
Less than 50k
👶 Age of investors
18 - 25
26 - 34
33%
35 - 90
67%
🙋 Legal gender of investors
Female
67%
Male
33%
Pearlers who invest in OPPT also invest in...
MHHT.AX was created on 2019-10-11 by Magellan. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Trust is to achieve attractive risk-adjusted returns over the medium to long-term.
📊 Share price
$1.86 AUD
🇦🇺 EX AUSTRALIA
🤖 TECHNOLOGY
💸 FINANCIALS
🛍️ CONSUMER
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
7.81%
📊 Share price
$73.69 AUD
⛳️ DIVERSIFIED
🌏 GLOBAL
MGOC.AX was created on 2007-07-01 by Magellan. The fund's investment portfolio concentrates primarily on total market equity. The investment objectives of the Fund are to achieve attractive risk-adjusted returns over the medium to long-term while reducing the risk of permanent capital loss. The Fund aims to deliver 9% p.a. net of fees over the economic cycle.
📊 Share price
$3.11 AUD
🛍️ CONSUMER
BKW
Brickworks Ltd. engages in the manufacture and distribution of building products. The company is headquartered in Sydney, New South Wales and currently employs 1,803 full-time employees. The Company’s divisions include Building Products Australia, Building Products North America, Industrial Property, and Investments. The Building Products Australia and Building Products North America segments manufacture and supply vitrified clay and concrete products used in the building industry. Its product lines include bricks, masonry blocks, pavers, roof tiles and roof battens used in the building industry. The Building Products Australia segment includes Austral Bricks (bricks producer) and other brands such as Austral Masonry and Bristile Roofing. Building Products North America is a brick producer in the north-east of the United States and includes the flagship brand of Glen-Gery. The Property segment utilizes opportunities associated with land owned by the Company, including the sale of property and investment in property trusts. The Investments segment holds investments in the Australian share market.
🙌 Performance (5Yr p.a)
13.97%
📊 Share price
$33.02 AUD
🕊️ SOCIALLY AWARE
📈 HIGH PRICE GROWTH
👷♀️ CONSTRUCTION
VGE.AX was created on 2013-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Seeks to track the return of the FTSE Emerging Markets All Cap China A Inclusion Index in Australian dollars, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
6.99%
📊 Share price
$90.77 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
Want more shares? Try these...
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
🙌 Performance (5Yr p.a)
-15.77%
📊 Share price
$0.60 AUD
🧬 BIOTECHNOLOGY
